PRESS RELEASE – Cognitive Research Corporation Names Patrick Simms as New COO

ST. PETERSBURG, FLORIDA | Cognitive Research Corporation (CRC), a leading neuroscience clinical services company, announced that Patrick Simms has been named Chief Operating Officer, reporting to Dr. Tom Hochadel, Co-Founder and Chief Executive Officer. CRC has been supporting clinical development for CNS-focused small to mid-size pharma, biotech, and medical device companies for over 16 years. The company has experienced explosive growth over the past five years as the CNS market has accelerated.

“CRC has seen significant increases in our client base and a corresponding increase in the complexity of the trials we are working on,” said Dr. Hochadel. “Our bright future underscores the need for us to constantly add to our executive team. Patrick’s extensive background in drug development both as a sponsor and a service provider has given him a complete understanding of today’s evolving drug development landscape. His leadership will be vital as we continue to expand our clinical services capabilities.”

“I have known the team at CRC for years and watched the company grow in all areas. CRC’s dedication to exceptional service and scientific precision sets them apart from many traditional CROs and is why so many of our clients return with additional studies. I look forward to guiding our clinical services team during this period of rapid growth,” said Simms.

Mr. Simms previously served as VP of Clinical Operations at multiple early-stage pharmaceutical and biotech companies in the U.S. and Asia. He has spent more than two decades in the life science sector leading clinical and regulatory teams in early and late stage drug development.

About Cognitive Research Corporation:
CRC’s mission is to support innovative companies developing new medicines and therapies to improve mental health. As a leading neuroscience clinical research organization (CRO) and technology company, CRC works with sponsors, specialized clinical trial sites, and CNS experts to bring new drugs through rigorous testing and ultimately to market. For more information visit: